InvestorsObserver is giving Vertex Pharmaceuticals Incorporated (VRTX) an Analyst Rating Rank of 29, meaning VRTX is ranked higher by analysts than 29% of stocks. The average price target for VRTX is $252 and analyst’s rate the stock as a Buy.
Wall Street analysts are rating VRTX a Buy today. Find out what this means to you and get the rest of the rankings on VRTX!